Fidaxomicin
Reduced fidaxomicin susceptibility may emerge during C. difficile treatment
Clostridioides difficile isolates with reduced fidaxomicin susceptibility may emerge during treatment and could spread to other patients, researchers found.
Health care professionals celebrate approval of treatment for late-stage cervical cancer
Should fidaxomicin be the preferred treatment for C. difficile?
New guidelines issued in 2021 stated a preference for fidaxomicin as first-line treatment for Clostridioides difficile infection, despite concerns about its cost.
Vancomycin, fidaxomicin use increases following revised C. difficile practice guidelines
Revised clinical practice guidelines for Clostridioides difficile that were published in February 2018 led to immediate, significant increases in oral vancomycin and fidaxomicin use in the United States, as well as a significant decrease in oral metronidazole use, according to findings published in Clinical Infectious Diseases.
FDA accepts sNDA for Dificid in children with C. difficile
The FDA accepted a new drug application for the oral suspension formulation of Dificid, Merck’s macrolide antibiotic. At the same time, it accepted a supplemental new drug application for the drug in tablet and oral suspension form for the treatment of Clostridioides difficile infection in children aged 6 months or older, Merck announced.